All Posts

Valuing science-driven companies is one of the hardest challenges in corporate finance. Whether a business is preclinical, commercialising, scaling, or preparing for a transaction, traditional metrics often fail to capture the true drivers of value: intellectual property, scientific progress, regulatory pathways, and multi-application technology platforms. At Sherwood, we work with companies across biotech, medtech, digital health, advanced manufacturing, AI, and deep tech to

Artificial intelligence is reshaping many aspects of business — including corporate finance. It can summarise documents, analyse data, and even produce draft valuation models or term sheet comments in seconds. Some clients have begun to ask whether AI can replace the need for an advisor altogether. It’s a fair question. But the short answer is:   AI can assist, not advise. 1. AI delivers general answers, not tailored advice AI produces outputs based on large, public data sets

The outlook isn't rosy—but could there be light at the end of the tunnel? The biopharma sector finds itself in uncertain territory, navigating a perfect storm of challenges—from looming tariff threats and unexpected regulatory shake-ups to deep R&D cuts and stubbornly high inflation. For industry leaders and investors alike, the stakes have rarely felt higher. While the road ahead may look daunting, understanding the landscape and preparing strategically could uncover hidden